×

Adjuvants for vaccines against respiratory syncytial virus

  • US 5,723,130 A
  • Filed: 09/16/1996
  • Issued: 03/03/1998
  • Est. Priority Date: 05/25/1993
  • Status: Expired due to Fees
First Claim
Patent Images

1. A vaccine formulation comprising (a) a respiratory syncytial viral (RSV) protein selected from the group consisting of (i) RSV glycoprotein G, (ii) RSV glycoprotein F, (iii) a chimeric glycoprotein consisting of the signal and extracellular domains of RSV glycoprotein F linked to the extracellular domain of RSV glycoprotein G, and (iv) combinations thereof, and (b) an adjuvant selected from the group consisting of QS-21, 3-deacylated monophosphoryl lipid A and combinations thereof, in a physiologically acceptable vehicle.

View all claims
  • 3 Assignments
Timeline View
Assignment View
    ×
    ×